The goal will be to address the risk of malnutrition and the loss of lean muscle mass while on the GLP-1 therapy and to avoid or limit weight rebound after the therapy
The 12S rRNA gene (MT-RNR1) spans approximately 6% of total mtDNA
Papageorgiou V, Apalla Z, Sotiriou E, Papageorgiou C, Lazaridou E, Vakirlis S, Ioannides D, Lallas A (2018) The Limitations of dermoscopy: false-positive and false-negative tumours
Enhanced Metabolic Health Experience improvements in blood sugar, blood pressure, cholesterol, and inflammatory markers
Probiotics ferment fiber during digestion, stimulating the production of short-chain fatty acids (SCFAs) that trigger GLP-1
The following additional adverse reactions have been identified during post approval use